Abstract
Protein tyrosine phosphatase 1B (PTP1B) has been implicated as one of the key negative regulators of insulin and leptin signal transduction pathways. PTP1B deficient mice are more sensitive to insulin, and have improved glycemic control and resistance to diet-induced obesity than the wild-type control mice. Inhibiting PTP1B action using antisense oligonucleotides and small molecule inhibitors represents novel therapeutic approach for the treatment of insulin resistance, type II diabetes, and obesity. The rapid development of this field is evidenced by the increasing number of patents and publications in recent years. This review will highlight the recent advances in various approaches for attenuating PTP1B action, particularly small molecule PTP1B inhibitors, and the challenges associated with developing PTP1B inhibitors with drug like properties.
Keywords: insulin resistance, type II diabetes, obesity, protein tyrosine phosphatase, antisense oligonucleotide, phosphotyrosyl mimetics, structure-based drug design, cellular permeability, second phosphotyrosyl binding site
Current Medicinal Chemistry
Title: Protein Tyrosine Phosphatase 1B Inhibition: Opportunities and Challenges
Volume: 10 Issue: 15
Author(s): Gang Liu
Affiliation:
Keywords: insulin resistance, type II diabetes, obesity, protein tyrosine phosphatase, antisense oligonucleotide, phosphotyrosyl mimetics, structure-based drug design, cellular permeability, second phosphotyrosyl binding site
Abstract: Protein tyrosine phosphatase 1B (PTP1B) has been implicated as one of the key negative regulators of insulin and leptin signal transduction pathways. PTP1B deficient mice are more sensitive to insulin, and have improved glycemic control and resistance to diet-induced obesity than the wild-type control mice. Inhibiting PTP1B action using antisense oligonucleotides and small molecule inhibitors represents novel therapeutic approach for the treatment of insulin resistance, type II diabetes, and obesity. The rapid development of this field is evidenced by the increasing number of patents and publications in recent years. This review will highlight the recent advances in various approaches for attenuating PTP1B action, particularly small molecule PTP1B inhibitors, and the challenges associated with developing PTP1B inhibitors with drug like properties.
Export Options
About this article
Cite this article as:
Liu Gang, Protein Tyrosine Phosphatase 1B Inhibition: Opportunities and Challenges, Current Medicinal Chemistry 2003; 10 (15) . https://dx.doi.org/10.2174/0929867033457296
DOI https://dx.doi.org/10.2174/0929867033457296 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gesture Interaction for Coronary Heart Diseases Based on Wavelet Transform and Semi-Continuous Hidden Markov Model in Augmented Reality
Recent Advances in Electrical & Electronic Engineering Progress in Development of Group A Streptococcus Vaccines
Current Pharmaceutical Biotechnology Sodium Selenite as an Anticancer Agent
Anti-Cancer Agents in Medicinal Chemistry Angiotensin II Receptor Blocker: Possibility of Antitumor Agent for Prostate Cancer
Mini-Reviews in Medicinal Chemistry Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Multifaceted Individualities in Pharmacological Treatments of Obesity
Current Clinical Pharmacology General or Local Anesthesia for TAVI? A Systematic Review of the Literature and Meta-Analysis
Current Pharmaceutical Design New Trends and Advances in Oral and Maxillofacial Imaging
Current Medical Imaging Homeobox Genes and Human Genetic Disorders
Current Molecular Medicine Mast Cell Chymase and Tryptase as Targets for Cardiovascular and Metabolic Diseases
Current Pharmaceutical Design Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery Viral Heart Disease and Acute Coronary Syndromes - Often or Rare Coexistence?
Current Pharmaceutical Design Clinical Profile of Relaxin, a Possible New Drug for Human Use
Current Drug Safety Drug Combinations for Dyslipidemia and Obesity Treatment in Metabolic Syndrome
Current Pharmaceutical Design Covid-19: An Update on Clinical Features, Diagnosis, and Treatment Strategies
Coronaviruses Role of Sulfur Containing Amino Acids as an Adjuvant Therapy in the Prevention of Diabetes and its Associated Complications
Current Diabetes Reviews An Update on the Cardiovascular Effects of Quercetin, a Plant Flavonoid
Current Nutrition & Food Science Potential Health Benefits of Berries
Current Nutrition & Food Science Blood Platelet Reactivity and its Pharmacological Modulation in (People with) Diabetes Mellitus
Current Pharmaceutical Design Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases
Current Pharmaceutical Design